US-based medical device company Taris Biomedical has begun the Phase Ib clinical trial of TAR-200 (GemRIS) in patients with muscle-invasive bladder cancer (MIBC).

TAR-200 is a drug-device combination product which uses the TARIS System, designed to release gemcitabine continuously into the bladder over seven days.

The open-label Phase Ib trial intends to determine the preliminary efficacy and tolerability of gemcitabine using TAR-200.

"TAR-200 has the potential to address patients underserved by the current standard of care."

It is expected to involve 20 patients diagnosed with MIBC before they undergo a radical cystectomy.

TARIS chief medical officer Christopher Cutie said: “Patients diagnosed with muscle-invasive bladder cancer often require complex treatment regimens, including systemic chemotherapy and radical cystectomy (complete surgical removal of the urinary bladder), a life-altering operation associated with significant morbidity and, in some cases, death.

“Unfortunately, one or both of these treatments are not suitable for many patients suffering from this potentially lethal disease.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“TAR-200 has the potential to address patients underserved by the current standard of care.”

Gemcitabine is used to treat multiple cancers alone and in combination with other chemotherapeutic drugs.

The TARIS System is a controlled release dosage form to be used in the bladder. It uses passive delivery principles for a continuous release of drug in the bladder over weeks to months.

It involves minimally invasive in-office procedures to be deployed and retrieved from the bladder. The technology enables drug release customised to specific treatment regimens of the patients.